Alex P. Hamilton sold $40k of MGRX
director at MANGOCEUTICALS, INC.. 125,000 shares at an average of $0.32, traded Jun 25, 2024, filed Jun 27, 2024.
Score components
- +15RoleDirector
- +6Trade size$40k at market
- +20Share of holdings soldSold 71% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +33.1%, 3m -27.2%, 6m -45.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-24-025489, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 25, 2024 | SOpen-market sale Common Stock | -16,574 | $0.31 | $5,138 | 158,426 | Jun 27, 2024 |
| Jun 26, 2024 | SOpen-market sale Common Stock | -108,426 | $0.32 | $35k | 50,000 | Jun 27, 2024 |
Related signals
Other insiders at MANGOCEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | MGRXsell MANGOCEUTICALS, INC. | Eugene M Johnston CFO | $3,884 3,333 shares | -3% | |
| 22Weak | MGRXsell MANGOCEUTICALS, INC. | Eugene M Johnston CFO | $5,975 5,000 shares | -4% | |
| 22Weak | MGRXsell MANGOCEUTICALS, INC. | Eugene M Johnston CFO | $11k 10,000 shares | -7% | |
| 46Moderate | MGRXsell MANGOCEUTICALS, INC. | Alex P. Hamilton director | $153k 125,000 shares | -97% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.